MBrace Therapeutics’ Post

If you get a chance, attend this session which is sure to be enlightening!

Twenty three companies will share from £12 million in funding that has been awarded to advance innovative cancer projects and will be shared by 16 projects led by small and medium-sized enterprises at various stages right from feasibility through to regulatory approval. They include industry-led research and development projects by Antikor Biopharma Ltd, Cell Guidance Systems, Coding Bio, Epitopea, Grey Wolf Therapeutics, Lentitek, Medannex Ltd, Mestag Therapeutics, Momentous Therapeutics Ltd, Pathios Therapeutics, Prokarium, QV Bioelectronics, Revolver Therapeutics, #Sferola, Theolytics, VacV Biotherapeutics Feasibility project by CREASALLIS, Galytx, Kargenera, New Path Molecular Research, #OligoTune, Proteotype Diagnostics & Xgenera Congratulations to you all and we look forward to hearing more about the results Find out more via UK Research and Innovation https://lnkd.in/eg5RsCu8 #CancerResearch #InnovationInHealthcare #SmallBusinessGrants #MedicalInnovation #HealthTech #ClinicalTrials #BiotechFunding #HealthcareInnovation #SMEFunding #ResearchAndDevelopment

💡Innovation💡comes with new ways of thinking. The Orbits Oncology team exemplifies innovative thinking with their competitive Digital Twin Organoid Platform, which helps #biopharma identify the best #Oncology drug candidates to move into #clinicaltrials. Here is why you want to take notice: ➡️Not only do they have a competitive #drugdevelopment predictive platform with peer-reviewed publications, but they also integrate into current laboratory clinical platforms, making it an efficient, seamless process. ➡️They are the only digital platform that is facility- and device-agnostic for advanced organoid analysis, allowing integration into existing biopharma workflows at their point-of-need, using a platform-as-a-service model. ➡️Their proof of concept pilot showed a 20X faster turnaround time vs current standards, which is highly competitive with ongoing research. They aim to save up to $300MM in drug candidate research with their advanced precision modules, whereas translation typically breaks between bench and clinic. Recognized by Nature Portfolio Publishing Journals and the Merck Digital Sciences Studio Orbits Oncology is bringing patients into the heart of drug discovery through the power of organoids. Ahmet Hamdi Cavusoglu Alexa Goldman Kudos to the founding team Abraham Lin, Edgar Cardenas De La Hoz, and Tyler Gilcrest Looking forward to your continued success and growing collaborations!!

Translating radiopharmaceuticals is a complex process that requires strong preclinical data. Invicro’s preclinical team collaborates with you to unlock critical insights into pharmacology, radiochemistry, dosimetry & biodistribution. Learn more about our preclinical capabilities in this infographic: https://hubs.ly/Q02r4l5X0 #radiopharmaceuticals #theranostics #oncology #radioligandtherapy #imagingCRO

Bolt Biotherapeutics is halting its lead cancer drug BDC-1001, laying off 50% of staff, and shifting focus to early-stage candidates BDC-3042 (Phase 1) and BDC-4182 (preclinical). Key Insights - ▪️ New Direction: Prioritizing innovative ISAC technology for anti-tumor responses. ▪️ Partnerships: Continued ISAC research supported by Genmab and Toray. ▪️ Leadership Change: Willie Quinn steps in as CEO. ▪️ Impact: Changes aim to extend cash runway into 2026; stock dropped 34%. Questions - ▪️ How will this strategic shift impact Bolt’s future? ▪️ Can ISAC technology succeed despite high risks? ▪️ What does this mean for cancer drug innovation? #Biotech #CancerResearch #ISAC #BoltBiotherapeutics

Stay up to date on all things #IO and register for tomorrow's #SITC Targets for Cancer IO: A Deep Dive into Clinical Consideration for CD3-Bispecifics and Costimulatory T cell Engagers in Solid #Tumors Webinar! Moderators: Jeremy Myers, PhD - EvolveImmune Therapeutics & Dimitris Skokos, PhD - Regeneron Pharmaceuticals, Inc. Faculty: John Desarjais, PhD - Xencor, Christian Klein, PhD - Roche Innovation Center Zurich & Elizabeth Pham, PhD - Amgen Inc. This webinar will address current studies to develop more effective, safer CD3-targeting bispecific T #cell engagers that maintain clinical efficacy within the immunosuppressive #TME while minimizing cytokine release and other on-target, off-tumor toxicities. Save your spot for tomorrow's webinar: go.sitcancer.org/3YtTUNh

Our portfolio company HAYA Therapeutics has been recognized by Labiotech.eu as one of the top 18 biotech startups in Switzerland, spotlighting its innovative approach to targeting non-coding RNAs to combat fibrotic diseases and age-related conditions: https://lnkd.in/gnPbAhQ As reported by The Financial Times, a groundbreaking anti-aging therapy that mimics regenerative processes seen in axolotl salamanders has shown promise in extending the lifespan of mice by 25%. Read more about the treatment that targets the pro-inflammatory protein IL-11: https://lnkd.in/guvdqyFH New hires at our portfolio companies: HAYA Therapeutics welcomes Eric Adam as their new COO, bringing his extensive experience from the pharmaceutical and diagnostics industries to support their growth and scientific exploration. Meanwhile, Auron Therapeutics, Inc. introduces Serge Messerlian to their board, enhancing their leadership as they advance their innovative cancer therapeutics platform. #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

We are glad to announce our evaluation and commercial use agreement with Inaphaea BioLabs. This agreement involves using Inaphaea's patient-derived cells (PDCs) for evaluation and commercial use within DLOC Biosystems' cutting-edge perfused 3D tissue on-chip models. Inaphaea will be able to deploy its biobank in DLOC's chips to develop advanced biological models that reflect real cancer biology and deliver high-quality, disease-relevant results for clients. The contract initially focuses on the development of up to four glioblastoma and one triple-negative breast cancer in-vitro 3D tumour models. DLOC and Inaphaea will then offer these models for commercial services. Additional PDCs from Inaphaea's portfolio of 66 cancer types can be incorporated anytime. This deal will advance both companies' in-vitro testing capabilities, enhance our service offerings and broaden our potential customer base. #Organonchip #microfluidics #PDCs #BioTech #DrugDiscovery #Assays #AssayDevelopment

Are you looking for a robust Western blot assay with high sensitivity to support your preclinical studies or clinical trials? Champions' advanced Western Blot platform was developed by our experts for target validation, model and sample characterization, detection of post-translational modifications, and more... Our assay platform delivers: ✅ Sensitivity at the picogram level, requiring only a few microliters of sample. ✅ Enhanced data quality and reproducibility through automated protein separation and immunodetection. ✅ Tailored assays with rapid turnaround to meet your unique needs. ✅ Compatibility with all of Champion's preclinical pharmacology platforms and is GCLP-compliant for clinical specialty testing. Count on Champions for precise and dependable Western Blot Assay for your preclinical studies. Reach out today to discuss how we can accelerate your research: https://hubs.li/Q02CFpb_0 #westernblot #Proteindetection #Drugdiscovery #Cancerresearch #oncology #medicinalchemistry #clinicalspecialtytesting

Heading to ISCT 2024? Our agenda is jam-packed with opportunities to explore and move forward with your advanced therapeutics — from exciting speakers to thought-provoking sessions, and educational posters you won't want to miss: 👉 End-to-end manufacturing of autologous CAR T cell therapies with a new cell therapy manufacturing platform 👉 Regulatory T cell expansion in the Xuri cell expansion system W25 👉 Closed, semi-automated harvest of iPSC scale-up workflow using the Sepax C-Pro with CultureWash protocol 👉 Optimization of multiplex CRISPR-Cas9 editing of human primary T cells using lipid nanoparticles (LNPs) and subsequent off-target evaluation 👉 Strategies for producing clinical and commercial RNA-LNP drug products And there's more...follow this link to discover all the ways you can connect with us at ISCT: https://lnkd.in/eFha4ZVT